An international research team has solved a medical puzzle that emerged during the COVID-19 pandemic: why a rare but serious blood clotting condition develops in a tiny fraction of people who receive certain adenovirus-based vaccines or contract a natural adenovirus infection.
The breakthrough centers on a case of mistaken identity within the immune system. Researchers found that in susceptible individuals, the body confuses a harmless adenovirus protein with platelet factor 4 (PF4), a protein crucial to blood clotting. This confusion triggers antibodies that activate dangerous clotting, a condition called vaccine-induced immune thrombocytopenia and thrombosis, or VITT.
The discovery, published in the New England Journal of Medicine, involved scientists from Flinders University in Australia, Greifswald University in Germany, McMaster University in Canada, and the University of Melbourne. Lead researcher Dr. Jing Jing Wang said the findings clear a path to prevention.
"By modifying or removing this specific adenovirus protein, future vaccines can avoid this extremely rare reaction while continuing to provide strong protection against disease," Wang said.
The journey to this answer took years. VITT first surfaced in 2021 after rollouts of the Oxford-AstraZeneca vaccine and other adenovirus vector vaccines. In 2022, Wang and Professor Tom Gordon decoded the structure of the harmful PF4 antibody and identified a genetic risk factor tied to an antibody gene called IGLV3.21*02. That discovery helped researchers connect cases across continents.
A crucial clue arrived in 2023 when Dr. Ted Warkentin at McMaster reported an identical condition in patients with natural adenovirus (common cold) infections, some fatal. Follow-up work in 2024 showed that antibodies from vaccine-related and infection-related cases were indistinguishable, pointing squarely at the adenovirus itself, not any vaccine ingredient, as the culprit.
But the exact mechanism remained hidden until now.
Wang's team used advanced mass spectrometry sequencing to reveal molecular mimicry: the adenovirus protein resembles PF4 so closely that the immune system gets fooled. In rare cases, a normal immune response to the virus protein spirals into a harmful autoimmune attack.
"This was the missing link that explains how a normal immune response can, in very rare cases, become harmful," Wang said.
Professor James McCluskey from the University of Melbourne called the work a major scientific milestone. "It is a brilliant piece of molecular sleuthing, the culmination of a body of work that unravels the genetic and structural basis for how a normal immune response to a virus protein leads to pathogenic autoimmunity," McCluskey said.
With the trigger identified, vaccine developers can now redesign the specific adenovirus protein, called pVII, to eliminate the mimicry without sacrificing protection. The findings should accelerate the development of safer vaccines that remain effective and broadly accessible, particularly in regions where adenovirus-based vaccines remain a cornerstone of disease prevention.
Author Jessica Williams: "This is the kind of detective work that turns a rare disaster into a solved engineering problem, and vaccine safety just got a genuine upgrade."
Comments